Medicus Pharma (NASDAQ:MDCX) Issues Quarterly Earnings Results

Medicus Pharma (NASDAQ:MDCX) posted its quarterly earnings results on Wednesday. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.50), Zacks reports.

Medicus Pharma Stock Performance

Shares of Medicus Pharma stock traded down $0.00 during trading on Thursday, reaching $0.49. 948,644 shares of the company’s stock were exchanged, compared to its average volume of 3,970,217. The company has a market cap of $12.52 million, a P/E ratio of -0.23 and a beta of -1.58. Medicus Pharma has a 1-year low of $0.37 and a 1-year high of $8.94. The firm’s 50-day moving average price is $1.01 and its 200 day moving average price is $1.74.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Private Advisor Group LLC grew its position in Medicus Pharma by 3.8% during the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock worth $351,000 after acquiring an additional 5,500 shares during the last quarter. Osaic Holdings Inc. boosted its stake in shares of Medicus Pharma by 180.0% during the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after purchasing an additional 9,000 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Medicus Pharma during the second quarter worth about $41,000. Commonwealth Equity Services LLC grew its holdings in shares of Medicus Pharma by 161.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after purchasing an additional 17,611 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB increased its stake in shares of Medicus Pharma by 100.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock valued at $78,000 after buying an additional 25,622 shares during the period.

Analyst Upgrades and Downgrades

MDCX has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and set a $27.00 target price on shares of Medicus Pharma in a report on Thursday, March 19th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Medicus Pharma presently has a consensus rating of “Hold” and an average target price of $23.50.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.